Cite

HARVARD Citation

    Brückl, W. et al. (2021). Afatinib as first-line treatment in patients with EGFR-mutated non-small cell lung cancer in routine clinical practice. Therapeutic advances in medical oncology. p. . [Online]. 
  
Back to record